Game Changer Biotech, established by De Montfort University for commercial enterprise, seeks to exploit the potential of 'game-changing' technologies through the establishment and funding of various spinout companies from the Faculty of Health and Life Science.
Starting with the exciting work of Professor Bob Chaudhuri, a leading, world-renowned expert in yeast expression systems, CYP Design Limited was established to advance new drug discovery. With bespoke tools for testing new compounds for their potential toxicity in humans, utilising cytochrome P450 (CYP) enzymes expressed in baker's yeast, significantly these CYP tools are stable at room temperature for greater transport and laboratory convenience. The yield, activity and results achieved using CYPs expressed in baker's yeast are often greater (and more relevant) than current market leaders' tools derived from insect cells. The CYP-design story continues with 'human CYPs in human cells' for greater biological relevance and the testing of short-listed compounds for new drug development.
Game Changer Biotech India, a manufacturing company based in New Delhi, was established to facilitate the commercial enterprise emerging from the collaboration of two leading institutions, De Montfort University (Leicester) and the Indian Institute of Integrative Medicine (IIIM, Jammu). DMU has expertise in 'biology' and proprietary knowledge in the use of enzymes for bio-transformations. IIIM has unrivalled expertise in 'chemistry' and access to unique, natural resources (indigenous plants, flowers and flora). Opportunities are being jointly developed from the Indo-UK collaboration in the field of drug discovery from natural products (medicinal plants and microbial species).Contact us today
Game Changer Biotech Limited, a full service company providing management and analysis of intellectual property, know-how and technology within the biotechnology sector for commercial exploitation. Identifying unique opportunities, partners for joint venture development, delivering viable opportunities to industry and commerce, and significant returns to private equity investors. Translating life science into desirable commercial solutions.Read More
Game Changer Biotech (India) Limited was established to develop and manufacture global products derived from natural resources utilising world leading chemistry and biology. The company is positioned to exploit 'bio-transformations' and develop products derived from the unique and natural resources of India.Read More
CYP Design Limited is dedicated to supporting drug research and development needs by offering stabilised, highly active cytochrome P450 (CYP) enzyme products. These products are presented in unique Sacchrosomes™ and are stable at room temperature. They provide pharma companies and contract research organisations with significant cost advantages as these products do not need to be shipped with dry-ice, or kept in cold storage before use; they provide greater convenience due to their stability at room temperature.Read More
April 2015: Game Changer Biotech supports Indo-UK academic collaborationGame Changer Biotech has secured the opportunity to commercialise the Intellectual Property developed from the collaboration between two leading academic institutions, IIIM (Indian Institute of Integrative Medicine, Jammu, India) and DMU (De Montfort University, Leicester, UK). A new joint-venture company, Game Changer Biotech India, has been established with the support of leading industrialists and private equity from the UK and India.
March 2015: SEIS & EIS Funding Round success to £500kCYP Design Limited successfully completed a £325,000 funding round in March 2015 with investors also taking advantage of the Enterprise Investment Scheme. This takes the total funds raised under SEIS and EIS to £500,000. The investment supports taking the company's technology in developing 'human CYPs in human cells' and larger-scale CYP enzyme production in yeast beyond the 'proof of concept' stage towards commercialisation.
Please do not hesitate to get in touch by using our Contact Us page should you wish to have more details on any of our news items.